Embark
Boston
About Embark
Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $94.3M
- Funding stage: Early Stage Venture
- Last round: Series B (Jul 2021)
- Website: embarkvet.com
- Phone: 1(224)236-2275
Industries & Categories
Health Care, Pet, Veterinary
Social Profiles
Canonical: https://fsome.com/organization/embark-58949 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.